TY - JOUR
T1 - Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)
AU - Yang, Kai Chun
AU - Liao, Yin To
AU - Yang, Yen Kuang
AU - Lin, Shih Ku
AU - Liang, Chih Sung
AU - Bai, Ya Mei
N1 - Funding Information:
The authors thank the experts of the scientific committee for their contributions to the formulation of the statements and the determination of the recommendation levels. The members of the committee are (listed according to the order of the last name) Dr Cheng-Sheng Chen (Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan), Dr Po-See Chen (Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan), Dr Shao-Tsu Chen (Department of Psychiatry, Buddhist Tzu Chi General Hospital, Hualien, Taiwan), Dr Yi-Ling Chien (Department of Psychiatry, College of Medicine, National Taiwan University, Taipei, Taiwan), Dr Nan-Ying Chiu (Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan), Dr Chun-Kai Fang (Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan), Dr Ming-Hsien Hsieh (Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan), Dr Yu-Shu Huang (Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan), Dr Chau-Shoun Lee (Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan), Dr Chun-Hung Lee (Department of Forensic and Addiction Psychiatry, Jianan Psychiatric Center, Ministry of Health and Welfare, Tainan, Taiwan), Dr Ching-Hua Lin (Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan), Dr Chia-Yih Liu (Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, Taiwan), Dr Lih-Jong Shen (Department of Mental and Oral Health, Ministry of Health and Welfare, Taipei, Taiwan) and Dr Yung-Chieh Yen (Department of Psychiatry, E-Da Hospital, Kaohsiung, Taiwan).
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2021/8
Y1 - 2021/8
N2 - Objective: Schizophrenia is a chronic, debilitating psychiatric disorder with a high risk of relapse. Nonadherence to medication is a significant contributor to poor outcomes. Although long-acting injectable (LAI) antipsychotics prevent the relapse of schizophrenia, several factors present obstacles to the use of LAI antipsychotics, and clinical guidelines for LAI antipsychotics remain limited. To provide clinical recommendations, the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) developed consensus statements for the effectiveness, target populations, initiation timing, and particular clinical situations for the use of LAI antipsychotics in patients with schizophrenia. Methods: After a systematic literature review, a working group drafted consensus statements for the selected clinical topics and determined the levels of evidence-based recommendation based on the latest World Federation of Societies of Biological Psychiatry grading system. A scientific committee evaluated the draft statements and decided the final recommendations regarding the grades by anonymous voting after incorporating clinical experience and practice into the evidence from research. Results: The TSBPN proposed ten consensus statements for the application of LAI antipsychotics. The current evidence supported that LAI antipsychotics could be a treatment option for all schizophrenia patients, including first-episode patients. LAI antipsychotics could be initiated both during an acute psychotic episode and when patients are stable. The consensus also gave recommendations for particular clinical situations with insufficient scientific data, such as for use in elderly or adolescent patients, patients with treatment-resistant schizophrenia, and breakthrough psychosis, and strategies to assist patients/caregivers with decision making. Conclusions: The consensus statements developed by the TSBPN provide evidence-based clinical recommendations and could give clinicians more confidence when prescribing LAI antipsychotics to treat schizophrenia, thereby improving treatment outcomes.
AB - Objective: Schizophrenia is a chronic, debilitating psychiatric disorder with a high risk of relapse. Nonadherence to medication is a significant contributor to poor outcomes. Although long-acting injectable (LAI) antipsychotics prevent the relapse of schizophrenia, several factors present obstacles to the use of LAI antipsychotics, and clinical guidelines for LAI antipsychotics remain limited. To provide clinical recommendations, the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) developed consensus statements for the effectiveness, target populations, initiation timing, and particular clinical situations for the use of LAI antipsychotics in patients with schizophrenia. Methods: After a systematic literature review, a working group drafted consensus statements for the selected clinical topics and determined the levels of evidence-based recommendation based on the latest World Federation of Societies of Biological Psychiatry grading system. A scientific committee evaluated the draft statements and decided the final recommendations regarding the grades by anonymous voting after incorporating clinical experience and practice into the evidence from research. Results: The TSBPN proposed ten consensus statements for the application of LAI antipsychotics. The current evidence supported that LAI antipsychotics could be a treatment option for all schizophrenia patients, including first-episode patients. LAI antipsychotics could be initiated both during an acute psychotic episode and when patients are stable. The consensus also gave recommendations for particular clinical situations with insufficient scientific data, such as for use in elderly or adolescent patients, patients with treatment-resistant schizophrenia, and breakthrough psychosis, and strategies to assist patients/caregivers with decision making. Conclusions: The consensus statements developed by the TSBPN provide evidence-based clinical recommendations and could give clinicians more confidence when prescribing LAI antipsychotics to treat schizophrenia, thereby improving treatment outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85111340839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111340839&partnerID=8YFLogxK
U2 - 10.1007/s40263-021-00838-5
DO - 10.1007/s40263-021-00838-5
M3 - Article
C2 - 34312788
AN - SCOPUS:85111340839
SN - 1172-7047
VL - 35
SP - 893
EP - 905
JO - CNS Drugs
JF - CNS Drugs
IS - 8
ER -